Back to top

Top Ranked Value Stocks to Buy for March 26th

Read MoreHide Full Article

Here are four stocks with buy rank and strong value characteristics for investors to consider today, March 26th:

K12 Inc. (LRN - Free Report) : This technology-based education company has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings advancing 25.5% over the last 60 days.

K12 Inc Price and Consensus

K12 Inc Price and Consensus

K12 Inc price-consensus-chart | K12 Inc Quote

K12 has a price-to-earnings ratio (P/E) of 22.83, compared with 45.60 for the industry. The company possesses a Value Score of A.

K12 Inc PE Ratio (TTM)

K12 Inc PE Ratio (TTM)

K12 Inc pe-ratio-ttm | K12 Inc Quote

Global Brass and Copper Holdings, Inc. (BRSS - Free Report) : This metal fabrication company has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 20.8% over the last 60 days.

Global Brass and Copper Holdings has a price-to-earnings ratio (P/E) of 9.51, compared with 16.60 for the industry. The company possesses a Value Score of A.

SP Plus Corporation (SP - Free Report) : This management services provider has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings advancing 18.8% over the last 60 days.

SP Plus has a price-to-earnings ratio (P/E) of 15.90, compared with 25.00 for the industry. The company possesses a Value Score of A.

Sony Corporation (SNE - Free Report) : This electronic equipment manufacturer has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 33.6% over the last 60 days.

Sony has a price-to-earnings ratio (P/E) of 12.42, compared with 22.30 for the industry. The company possesses a Value Score of A.

See the full list of top ranked stocks here

Learn more about the Value score and how it is calculated here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>



More from Zacks Zacks #1 Rank Additions

You May Like